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Vaccines and the Public Health Trust
Objectives
1. Review the impact of immunizations on the public 
health over the past 50 years.
2. Childhood Vaccines Now
3. Describe the challenges associated with  trying to 
eliminate “immunizable” diseases. 
Examples: Invasive Pneumoccal Disease
Neisseria meningitis
4. The Future
Before 1970
n 1949: Smallbox eliminated in the U.S.
n 1950s: Salk and Sabin polio vaccines
n 1963: Measles vaccine
n 1966: Hilleman isolates Jeryl Lynn strain 
of mumps
Atkinson.Epidemiol Preven Vacc Prev Dis. CDC, 2006
1970s – 1980s
n 1977: Smallpox eliminated from the planet
n 1979: Polio eliminated in the U.S.
n 1985: H. influenzae polysaccharide vaccine (PRP)
n 1986: First cancer vaccine (HepB)
n 1987: First polysaccharide conjugate (Hib PRP-D)
n 1989: Measles resurgence in the U.S.
Atkinson.Epidemiol Preven Vacc Prev Dis. CDC, 2006
1990s
n 1991: Polio eliminated in the Western hemisphere
n 1994: Measles eliminated in the U.K.
n 1995: First live-attenuated herpesvirus vaccine 
(varicella)
n 1996: Acellular pertussis vaccine (DTaP)
n 1998: First live reassortant vaccine (RRV-TV)
n 1999: RRV-TV withdrawn
Atkinson.Epidemiol Preven Vacc Prev Dis. CDC, 2006
2000s
n 2000: Measles eliminated in the U.S.
n 2000: OPV recommendation withdrawn in the U.S.
n 2002: First DTaP-based multivalent combination 
vaccine (DTaP-HepB-IPV)
n 2003: First intranasal vaccine (LAIV)
n 2004: Rubella eliminated in the U.S.
n 2005: Bird Flu Pandemic
n 2006: Second cancer vaccine (HPV)
n 2009: H1N1 Pandemic
Atkinson.Epidemiol Preven Vacc Prev Dis. CDC, 2006
2010s
n 2012:  MERS Outbreak
n 2012:  Menigitis B Vaccines Introduced
n 2014:  Ebola Outbreak
n 2019:  Coronavirus Pandemic
Annual Disease Burden
Disease Peak 2004-06
Cases Deaths Cases Deaths
Diphtheria 30,508 3,075 0 0
Measles 763,094 552 55 0
Mumps 212,932 50 6,584 0
Pertussis 265,269 7,518 15,632 27
Polio 42,033 2,720 0 0
CRS 20,000 2,160 1 0
Smallpox 110,672 2,510 0 0
Tetanus 601 511 41 4
Roush, JAMA 2007; 298:2155 (vaccine programs before 1980)
Annual Disease Burden
Disease Peak 2004-06
Cases Deaths Cases Deaths
Hepatitis A 254,518 298 15,298 18
Hepatitis B 74,361 267 13,169 47
Hib >20,000 >1,000 <50 <5
IPD 64,400 7,300 41,550 4,850
Varicella 5,358,595 138 612,768 19
Roush, JAMA 2007; 298:2155 (vaccine programs after 1980)
Clinically Preventable Burden
Coeffield. Am J Prev Med 2001; 21:1
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Cost-Utility
Coeffield. Am J Prev Med 2001; 21:1
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Benefits of Vaccination
Vaccine Programs 2001 Birth Cohort (N=3,803,295)
Cases Deaths Total Costs
Without 14,330,376 33,564 $46,557 million
With 708,372 463 $482 million
↑DTaP, Hib, IPV, MMR, HepB, varicella (not included: HepA, PCV-7, ifluenza, MCV-4)
For every dollar spent, vaccine programs saved $5 in direct medical
costs and an additional $11 in societal costs
Zhou F et al. Arch Pediatr Adolesc Med 2005; 159: 1136-1144
Birth to 15 Months
18 Months to 18 Years
Children Age 4 Months through 6 
Years
Children and Adolescents Age 7 
through 18 Years
Why the Routine Vaccine Schedule Changes
New Vaccine for old disease Hib polysaccharide; HepA; varicella; 
rotavirus; HPV
Old vaccine for new disease Zoster vaccine
Improved vaccine Recombinant HepB; DTaP; 
PCV7;Hib conjugate; MCV4; LAIV
Expansion to new age group Hib at 2 mo; HepA at 12 mo; Tdap 
for adolescents and adults
Conversion from targeted to universal 
program
HepA; HepB; influenza for young 
children; MCV4 for all adolescents
Change in dosing schedule Elimination of OPV at 6 mo
New program goal Second MMR; second varicella; 
influenza for all children
Altered risk/benefit ratio All-IPV schedule
Safety issue Withdrawal of RRV-TV
Eradication Withdrawal of vaccinia
Immediate Remaining Challenges
n Residual disease
n Delivery 
n Cost
n Public confidence
n New target groups
Residual Disease: Pertussis
CDC. Epidemiology and Prevention of Vaccine-Preventable Disease 8th ed. 2004;75
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But…
n25-fold increase in cases since 1976
nUp to 5 million cases per year among individuals ages 15-65 
(based on seroconversion rates)
Clin infect Dis 43:151 (2006)
Recommendation; Tdap booster at age 11-12 (approved 10-64)
Invasive Pneumococcal 
Disease
Whitney C et al. N Engl J Med 2003;348:1737-1746
Rates of Invasive Pneumococcal Disease among Children under Five Years Old, According to 
Age and Year
Kyaw M et al. N Engl J Med 2006;354:1455-1463
Annual Incidence of Invasive Disease Caused by Penicillin-Susceptible and Penicillin-
Nonsusceptible Pneumococci among Children under Two Years of Age, 1996 to 2004
Whitney C et al. N Engl J Med 2003;348:1737-1746
Rates of Invasive Pneumococcal Disease among Persons at Least Five Years Old, 
According to Age Group and Year
The “Replacement Effect”
Increase in Invasive Disease by Non-Vaccine Serotypes
JAMA 297(16): 1784 (2007)
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Invasive Pneumococcal Disease (IPD)
10 U.S. Sites (2007)
Age (mos) All IPD PCV Serotypes Serotype 19A
< 12 155 104 60
12-23 124 73 57
24-35 71 43 32
36-47 48 34 20
48-59 29 20 11
All < 60 427 274 180
MMWR 59: 253 (2010)
Pneumococcal Vaccine Serotypes
PCV 7: 4, 6B, 9V, 14, 18C, 19F, 23F
PCV 13: PCV7 + 1, 3, 5, 6A, 7F, 19A
New:  22F, 33F, others
Case
n An 18-year-old male is admitted through 
the emergency room with a 12-hour 
history of fever, rigors, stiffneck and 
headache.  He noted a rash 3-4 hours 
before going to the ER. 
n He is a freshman at the University of the 
Arts, but lives off campus with a new 
girlfriend.



Neisseria meningitidis
n Gram-negative diplococcus
n Polysaccharide capsule determines 
serogroup (13 serogroups)
n Nasophayngeal carriage is an immunizing 
state
n Transmission via respiratory route
n Invasive disease occurs in newly infected

N. meningitidis Disease
n Leading cause of bacterial meningitis in 
children and young adults
n Cases are sporadic (95-97%) or via 
outbreaks (increasing)
n Case fatality rate: 10-13%
n Morbidity (11-19%): neurologic, limb loss, 
hearing loss

N. meningitidis Disease
n 2400-3000 cases/year (0.8-1.3 cases/100,000)
n Highest rate in infants < 1 year old
n 3% of cases (1998-1999) in college students
n Individuals 18-23 yo have a higher rate  (1.4 
cases/100,000)
n College freshman living in dorms have a much 
higher rate (4.6 cases/100,000)


Meningococcal Conjugate Vaccines
n Recommended for adolescents aged 11-18 
years and others at increased risk for 
meningococcal disease
n MCV4-D (Sanofi) licensed for persons 2-55 years
n MenACWY-CRM197 (Novartis) licensed 2/19/2010 for 
persons aged 11-55 years.
n Infant vaccines in late-stage development
n HibMenCY (GSK): 2,4,6, and 12-15 months*
n MenACWY-CRM197: 2,4,6 and 12-15 months
n MCV4-D: 9 and 12 months
Why no vaccine against serogroup B?
n Meningococci differentiated by capsular type
n Vaccines are conjugated capsular polysaccharide-
protein complexes
n Serogroup B polysaccharide capsule has structural 
homology with neural cell adhesion molecule
n Fear of inducing autoimmune response
n Development of a vaccine against serogroup B 
focusing on outer membrane proteins




Public Concerns About Vaccines
Concern Proposed Mechanism Implicated Vaccines
Encephalopathy Toxins DTP
Allergy Hygeine Hypothesis All
Autoimmunity Molecular mimicry Many
SIDS Toxins DTP, HepB
Mad Cow Disease Prions Many
AIDS SIV contamination OPV
Cancer SV40 contamination OPV
Neurological damage Thimerosal Many
Autism Bowel inflammation MMR
The Future:
New technology for coronavirus vaccines
n mRNA codes for spike protein 
¨ Moderna
¨ Pfizer/BioNTech
n DNA Plasmid
¨ Inovio
n Intranasal recombinant adenovirus + 
CoV-2 protein
¨ J & J/Janssen
n DNA inserted into bacteria to produce spike protein
¨ Sanofi/GSK (adjuvant)
Vaccines: Conclusions
1. Vaccinating at-risk populations is our single 
most important medical intervention
2. The risks of not vaccinating far outweigh the 
risks of vaccinating.
3. Physicians need to be ready with scientific 
data when confronting parents who decline 
recommended immunizations.
4. Science rules!  We will have a covid-19 
vaccine.
